重症肌无力-话题@MedSci

#重症肌无力#

14篇内容 | 4272人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2128499, encodeId=8b24212849991, content=<a href='/topic/show?id=fbd825321ba' target=_blank style='color:#2F92EE;'>#他克莫司#</a>与单<a href='/topic/show?id=62d2e6828cc' target=_blank style='color:#2F92EE;'>#糖皮质激素#</a>治疗<a href='/topic/show?id=910e959e0c9' target=_blank style='color:#2F92EE;'>#重症肌无力#</a>的比较，前者可能更为有利！未来有可能会对他克莫司进一步改良的可能？, objectTitle=Ann Clin Transl Neurol：单他克莫司与单糖皮质激素治疗重症肌无力的比较, objectType=article, longId=768794, objectId=bf0ae68794cc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668024264698_4754896.jpeg, objectUrl=/article/show_article.do?id=bf0ae68794cc, replyNumber=0, likeNumber=144, createdTime=2023-04-26, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=香港, moduleDTOList=[ModuleDTO(moduleId=bf0ae68794cc, moduleTitle=Ann Clin Transl Neurol：单他克莫司与单糖皮质激素治疗重症肌无力的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf0ae68794cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2124078, encodeId=f2d521240e8a4, content=<a href='/topic/show?id=2b47105815cc' target=_blank style='color:#2F92EE;'>#早期快速作用治疗#</a>（EFT）被定义为在治疗的早期阶段积极使用非口服快速作用免疫疗法，包括<a href='/topic/show?id=e75889215f7' target=_blank style='color:#2F92EE;'>#血浆置换#</a>、静脉<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>和/或静脉注射高剂量<a href='/topic/show?id=394969e8925' target=_blank style='color:#2F92EE;'>#甲基强的松龙#</a>（IVMP）.EFT与完全稳定缓解率和类固醇相关并发症减少率相似。<a href='/topic/show?id=910e959e0c9' target=_blank style='color:#2F92EE;'>#重症肌无力#</a>, objectTitle=JNNP:早期治疗全身性重症肌无力的疗效, objectType=article, longId=759402, objectId=0beee5940229, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668025471172_4754896.webp, objectUrl=/article/show_article.do?id=0beee5940229, replyNumber=0, likeNumber=143, createdTime=2023-04-06, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0beee5940229, moduleTitle=JNNP:早期治疗全身性重症肌无力的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0beee5940229)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1220363, encodeId=fa67122036378, content=<a href='/topic/show?id=820e3228e1b' target=_blank style='color:#2F92EE;'>#利妥昔单抗#</a><a href='/topic/show?id=910e959e0c9' target=_blank style='color:#2F92EE;'>#重症肌无力#</a>, objectTitle=JNNP:厄瓜利珠单抗与利妥昔单抗治疗全身性重症肌无力的比较, objectType=article, longId=300333, objectId=438830033364, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202238/1646751656574_2119349.jpg, objectUrl=/article/show_article.do?id=438830033364, replyNumber=0, likeNumber=164, createdTime=2022-05-17, rootId=0, userName=赛华佗, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=438830033364, moduleTitle=JNNP:厄瓜利珠单抗与利妥昔单抗治疗全身性重症肌无力的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=438830033364)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1063021, encodeId=f59f10630213c, content=<a href='/topic/show?id=910e959e0c9' target=_blank style='color:#2F92EE;'>#重症肌无力#</a>期待早日研发出特效药, objectTitle=重症肌无力, objectType=topic, longId=95970, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=127, createdTime=2021-10-22, rootId=0, userName=ms7000000169409063, userId=a0e85397868, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1009361, encodeId=2cdf1009361cc, content=<a href='/topic/show?id=910e959e0c9' target=_blank style='color:#2F92EE;'>#重症肌无力#</a>终于有药物治疗了<a href='/topic/show?id=67b110438e11' target=_blank style='color:#2F92EE;'>#艾加莫德#</a>, objectTitle=抗体片段efgartigimod治疗重症肌无力：III期试验迎硕果！, objectType=article, longId=194860, objectId=254019486069, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020527/1590564295541_5295902.jpeg, objectUrl=/article/show_article.do?id=254019486069, replyNumber=0, likeNumber=162, createdTime=2021-08-19, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=254019486069, moduleTitle=抗体片段efgartigimod治疗重症肌无力：III期试验迎硕果！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=254019486069)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=973232, encodeId=477a9e323287, content=YY默默哦呢<a href='/topic/show?id=910e959e0c9' target=_blank style='color:#2F92EE;'>#重症肌无力#</a>, objectTitle=J Clin Oncol：基于分子和临床病理特征的临床计算器可预测I-III期结肠癌术后的复发风险, objectType=article, longId=206356, objectId=669420635671, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/03c6505b36012caf29ea7e5b6940b3e7a9fd349b.jpg, objectUrl=/article/show_article.do?id=669420635671, replyNumber=0, likeNumber=148, createdTime=2021-06-13, rootId=0, userName=ms3000000546125468, userId=336e5429283, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=669420635671, moduleTitle=J Clin Oncol：基于分子和临床病理特征的临床计算器可预测I-III期结肠癌术后的复发风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=669420635671)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=924472, encodeId=92009244e267, content=<a href='/topic/show?id=910e959e0c9' target=_blank style='color:#2F92EE;'>#重症肌无力#</a>, objectTitle=JAMA neurology：重症肌无力患者不同激素治疗方案的效果比较, objectType=article, longId=207109, objectId=94f720e10924, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021213/1613209241764_2299762.png, objectUrl=/article/show_article.do?id=94f720e10924, replyNumber=0, likeNumber=184, createdTime=2021-02-13, rootId=0, userName=健康达人, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94f720e10924, moduleTitle=JAMA neurology：重症肌无力患者不同激素治疗方案的效果比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94f720e10924)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=904293, encodeId=d79a9042933c, content=<a href='/topic/show?id=910e959e0c9' target=_blank style='color:#2F92EE;'>#重症肌无力#</a>上市时间？, objectTitle=JAMA Neurol：Zillucoplan用于治疗中重度全身性重症肌无力, objectType=article, longId=188393, objectId=6b1e188393a7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/202002/20200218190854163.jpg, objectUrl=/article/show_article.do?id=6b1e188393a7, replyNumber=0, likeNumber=192, createdTime=2020-12-02, rootId=0, userName=lifefamily, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b1e188393a7, moduleTitle=JAMA Neurol：Zillucoplan用于治疗中重度全身性重症肌无力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b1e188393a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=904292, encodeId=d5f790429253, content=<a href='/topic/show?id=910e959e0c9' target=_blank style='color:#2F92EE;'>#重症肌无力#</a>的<a href='/topic/show?id=5a8be955621' target=_blank style='color:#2F92EE;'>#罕见病#</a>, objectTitle=JAMA Neurol：利妥昔单抗治疗新发全身性重症肌无力, objectType=article, longId=193615, objectId=8cad19361569, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202056/1588763363442_2051781.jpg, objectUrl=/article/show_article.do?id=8cad19361569, replyNumber=0, likeNumber=220, createdTime=2020-12-02, rootId=0, userName=lifefamily, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8cad19361569, moduleTitle=JAMA Neurol：利妥昔单抗治疗新发全身性重症肌无力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8cad19361569)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

重症肌无力

2020-05-29发表于威斯康星

侠胆医心

#他克莫司#与单#糖皮质激素#治疗#重症肌无力#的比较，前者可能更为有利！未来有可能会对他克莫司进一步改良的可能？

Ann Clin Transl Neurol：单他克莫司与单糖皮质激素治疗重症肌无力的比较

2023-04-26发表于香港

侠胆医心

#早期快速作用治疗#（EFT）被定义为在治疗的早期阶段积极使用非口服快速作用免疫疗法，包括#血浆置换#、静脉#免疫球蛋白#和/或静脉注射高剂量#甲基强的松龙#（IVMP）.EFT与完全稳定缓解率和类固醇相关并发症减少率相似。#重症肌无力#

JNNP:早期治疗全身性重症肌无力的疗效

2023-04-06发表于上海

赛华佗

#利妥昔单抗##重症肌无力#

JNNP:厄瓜利珠单抗与利妥昔单抗治疗全身性重症肌无力的比较

2022-05-17

ms7000000169409063

#重症肌无力#期待早日研发出特效药

2021-10-22

病毒猎手

#重症肌无力#终于有药物治疗了#艾加莫德#

抗体片段efgartigimod治疗重症肌无力：III期试验迎硕果！

2021-08-19

ms3000000546125468

YY默默哦呢#重症肌无力#

J Clin Oncol：基于分子和临床病理特征的临床计算器可预测I-III期结肠癌术后的复发风险

2021-06-13

健康达人

#重症肌无力#

JAMA neurology：重症肌无力患者不同激素治疗方案的效果比较

2021-02-13

lifefamily

#重症肌无力#上市时间？

JAMA Neurol：Zillucoplan用于治疗中重度全身性重症肌无力

2020-12-02

lifefamily

#重症肌无力#的#罕见病#

JAMA Neurol：利妥昔单抗治疗新发全身性重症肌无力

2020-12-02